Chiusura precedente | 74,46 |
Aperto | 74,58 |
Denaro | 75,40 x 800 |
Lettera | 75,41 x 1000 |
Min-Max giorno | 74,57 - 75,52 |
Intervallo di 52 settimane | 53,22 - 80,59 |
Volume | |
Media Volume | 11.754.214 |
Capitalizzazione | 160,903B |
Beta (5 anni mensile) | 0,39 |
Rapporto PE (ttm) | 25,03 |
EPS (ttm) | 3,01 |
Prossima data utili | 26 ott 2022 |
Rendimento e dividendo (forward) | 2,16 (2,88%) |
Data ex dividendo | 30 giu 2022 |
Stima target 1A | 81,38 |
NEW ORLEANS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion
CEDARHURST, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To learn
NEW ORLEANS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To le